4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Pite> 98.5% (HPLC) Lenvatinib Mesylate Faktori Entèmedyè

Deskripsyon kout:

Non: 4-Chloro-7-Methoxyquinoline-6-Carboxamide

CAS: 417721-36-9

Pite:> 98.5% (HPLC)

Aparans: Off-White pou limyè jòn poud

Entèmedyè nan Lenvatinib Mesylate CAS 857890-39-2

Segondè Kalite, Pwodiksyon Komèsyal

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Ruifu Chimik Pwovizyon pou Lenvatinib Mesylate Entèmedyè ak Pite segondè
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Pwopriyete chimik:

Non Chimik	4-Chloro-7-Methoxyquinoline-6-Carboxamide
Sinonim	4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib enpurte 12;Lenvatinib enpurite B;Lenvatinib enpurite LFS-B
Nimewo CAS	417721-36-9
Nimewo CAT	RF-PI1971
Estati Stock	Nan Stock, Kapasite Pwodiksyon 50MT / Ane
Fòmil molekilè	C11H9ClN2O2
Pwa molekilè	236.65
Pwen k ap fonn	> 205 ℃ (desanm)
Dansite	1.380±0.060 g/cm3
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Off-blan pou limyè jòn poud
Pite / Metòd analiz	>98.5% (HPLC)
Pèt sou siye	<0.50%
Rezid sou ignisyon	<0.50%
Enpurte total	<1.50%
Spectre proton RMN	Konfòm ak estrikti
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2)

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) se sitou itilize kòm yon entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2).Devlope pa Eisai Inc., lenvatinib mesylate se yon inibitè reseptè faktè kwasans endothelial vaskilè (VEGF) ki gen aktivite kont VEGF subtip 1, 2, ak 3 e li te apwouve pa FDA an 2015 pou tretman kansè tiwoyid diferansye ki swa lokalman. frekan, metastatik, oswa pwogresif epi li pa t reponn ak tretman yòd radyo-aktif.Nan mwa me 2016, FDA te apwouve dwòg la kòm yon terapi konbinezon ak everolimus pou tretman kansè nan selil ren avanse.Paske VEGF (ak reseptè faktè kwasans fibroblast, ke yo rekonèt kòm FGFRs) yo panse yo jwe yon wòl nan chemen siyal kadyovaskilè, VEGF2R ak FGFR anpèchman yo panse yo dwe mekanis yo dèyè efè segondè prensipal lenvatinib mesylate, ki se tansyon wo.